Health Canada is proposing to disclose more confidential business information (CBI) to eligible persons for the purpose of protecting or promoting human health or the safety of the public, according to new draft guidance.
The disclosure of such CBI, approved under the Protecting Canadians from Unsafe Drugs Act (also known as Vanessa's Law) of 2014, stipulates that the Minister of Health may disclose CBI “about a therapeutic product without notifying the person to whose business or affairs the information relates or obtaining their consent, if the purpose of the disclosure is related to the protection or promotion of human health or the safety of the public and the disclosure is to a government; a person from whom the Minister seeks advice; or a person who carries out functions relating to the protection or promotion of human health or the safety of the public.”
The disclosure of such CBI can be for prescription and non-prescription drugs, vaccines, blood and blood products, radiopharmaceuticals, donor semen for assisted conception, gene and cell therapies, tissues and organs and medical devices. But the disclosures do not apply to CBI related to natural health products.
The review process what will be disclosed is overseen by a committee of senior Health Canada officials mandated to recommend a decision based on relevant technical and scientific expertise. The committee’s recommendation is also considered by a senior Health Canada official not involved in the review process who has been designated to exercise the Minister's authority.
Requesters of such CBI disclosures are required to confirm that the project for which they request disclosure of CBI is for a non-commercial purpose.
Health Canada also requires requesters to complete a Conflict of Interest declaration, which will helpt to determine whether or not to disclose CBI to a requester whose financial interests, employment and other affiliations could conflict with their commitment to use the CBI exclusively for non-commercial purposes that supports the protection or promotion of human health or the safety of the public.
The nine-step process for requesting the release of such CBI is as follows:
Comments on the draft guidance should be provided to Health Canada within 75 days from the date of this notice.
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.